Therefore, in ER+ breast cancer, the downregulation of K18 leads to the disinhibition of LRP16 nuclear action and the continuous activation of the ERα signaling pathway, to promote the growth and proliferation of breast cancer cells. This evidence concerns the gene ESR1 and breast cancer.